as 12-18-2024 10:41am EST
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Founded: | 2010 | Country: | United States |
Employees: | N/A | City: | YARDLEY |
Market Cap: | 78.4M | IPO Year: | 2017 |
Target Price: | $3.00 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.29 | EPS Growth: | N/A |
52 Week Low/High: | $0.32 - $2.10 | Next Earning Date: | 11-12-2024 |
Revenue: | $75,672,000 | Revenue Growth: | 5.13% |
Revenue Growth (this year): | 13.42% | Revenue Growth (next year): | 52.99% |
OPTN Breaking Stock News: Dive into OPTN Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
GuruFocus.com
a month ago
Thomson Reuters StreetEvents
a month ago
Zacks
a month ago
GlobeNewswire
a month ago
GuruFocus.com
a month ago
The information presented on this page, "OPTN OptiNose Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.